Coherus Oncology: 3 Key Takeaways for Long-Term Investors

Impact · against what's priced in

Coherus Oncology is in a precarious liquidity position with less than 12 months of cash, making its 30% workforce reduction a necessary but insufficient step for stability. While LOQTORZI sales are growing, they currently cover less than half of the reduced quarterly cash burn, leaving the company reliant on rapid regulatory progress for tagmokitug or external financing.

CHRS−0.20

No priced-in read yet